Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

The Landscape of Dynamic Genetic Changes in Ibrutinib-Treated CLL

Dan A. Landau, MD PhD, Clare Sun, MD, Daniel Rosebrock, Mariela Campbell, Sarah E. M. Herman, PhD, Julia Hoellenriegel, MS, Mohammed Farooqui, Wandi Zhang, MD, Donna S. Neuberg, ScD, Dimitri Livitz, Ignaty Leshchiner, Gad Getz, PhD, Jan Burger, MD PhD, Adrian Wiestner, MD PhD, Catherine J Wu, MD

Blood (2016) 128 (22): 188.

DOI: https://doi.org/10.1182/blood.V128.22.188.188

Published: 2016

Journal Articles

Identification of B Cell Receptor Antigens in the Chronic Lymphocytic Leukemia Microenvironment

Elisa ten Hacken, PhD, Thomas Oellerich, MD, Maria Gounari, PhD, Julia Hoellenriegel, MS, Kuan-Ting Pan, PhD, Susan O'Brien, MD, William Wierda, MD PhD, Alessandra Ferrajoli, MD, Zeev Estrov, MD, Michael J. Keating, MD, Henning Urlaub, PhD, Paolo Ghia, MD PhD, Jan A. Burger, MD PhD

Blood (2015) 126 (23): 2922.

DOI: https://doi.org/10.1182/blood.V126.23.2922.2922

Published: 2015

Journal Articles

The Spiegelmer NOX-A12, a novel CXCL12 inhibitor, interferes with chronic lymphocytic leukemia cell motility and causes chemosensitization

Julia Hoellenriegel, Dirk Zboralski, Christian Maasch, Nathalie Y. Rosin, William G. Wierda, Michael J. Keating, Anna Kruschinski, Jan A. Burger

Blood (2014) 123 (7): 1032–1039.

DOI: https://doi.org/10.1182/blood-2013-03-493924

Published: 2014

Includes: Supplemental data

Journal Articles

Longitudinal Gene Expression Profiling Reveals Down-Regulation Of BCR Signaling-Related Genes In Chronic Lymphocytic Leukemia (CLL) Patients Treated With Ibrutinib Plus Rituximab

Julia Hoellenriegel, Elena Hartmann, MD, PhD, Andreas Rosenwald, MD, Susan O'Brien, MD, Michael Keating, MD, William G. Wierda, MD, PhD, Joseph J. Buggy, PhD, Jan A. Burger, MD, PhD

Blood (2013) 122 (21): 1631.

DOI: https://doi.org/10.1182/blood.V122.21.1631.1631

Published: 2013

Journal Articles

Clonal Evolution In Patients With Chronic Lymphocytic Leukemia (CLL) Developing Resistance To BTK Inhibition

Jan A. Burger, MD, PhD, Dan Landau, M.D., Julia Hoellenriegel, Carrie Sougnez, Matthias Schlesner, Naveed Ishaque, Benedikt Brors, Michael J. Keating, MD, William G. Wierda, MD, Kristian Cibulskis, Hagop M. Kantarjian, MD, Susan M. O'Brien, MD, Donna S. Neuberg, ScD, Thorsten Zenz, MD, Gad Getz, Catherine J Wu, MD

Blood (2013) 122 (21): 866.

DOI: https://doi.org/10.1182/blood.V122.21.866.866

Published: 2013

Journal Articles

Ibrutinib In Combination With Rituximab (iR) Is Well Tolerated and Induces a High Rate Of Durable Remissions In Patients With High-Risk Chronic Lymphocytic Leukemia (CLL): New, Updated Results Of a Phase II Trial In 40 Patients

Jan A. Burger, MD, PhD, Michael J. Keating, MD, William G. Wierda, MD, PhD, Julia Hoellenriegel, Ghayathri Jeyakumar, MD, Alessandra Ferrajoli, MD, Stefan H. Faderl, MD, Marylou Cardenas-Turanzas, MD, Dr PH, Susan Lerner, MS, Gracy Zacharian, Xuelin Huang, Hagop M. Kantarjian, MD, Susan O'Brien, MD

Blood (2013) 122 (21): 675.

DOI: https://doi.org/10.1182/blood.V122.21.675.675

Published: 2013

Journal Articles

Mode of Action of the SDF-1/CXCL12 Inhibiting Spiegelmer ® Nox-A12 and Its Impact On Chronic Lymphocytic Leukemia (CLL) Cell Motility and Chemosensitization

Dirk Zboralski, PhD, Julia Hoellenriegel, Christian Maasch, PhD, Anna Kruschinski, PhD, Jan A. Burger, MD, PhD

Blood (2012) 120 (21): 318.

DOI: https://doi.org/10.1182/blood.V120.21.318.318

Published: 2012

Journal Articles

In Vivo Inhibition of BCR Activation in High-Risk CLL Patients On Therapy with Bruton's Tyrosine Kinase Inhibitor Ibrutinib: Correlative Studies from an Ongoing Phase 2 Clinical Trial

Julia Hoellenriegel, Susan O'Brien, MD, Michael J. Keating, MD, William G. Wierda, MD, PhD, Joseph J. Buggy, PhD, Jan A. Burger, MD, PhD

Blood (2012) 120 (21): 186.

DOI: https://doi.org/10.1182/blood.V120.21.186.186

Published: 2012

Journal Articles

The Btk Inhibitor Ibrutinib (PCI-32765) in Combination with Rituximab Is Well Tolerated and Displays Profound Activity in High-Risk Chronic Lymphocytic Leukemia (CLL) Patients

Jan A. Burger, MD, PhD, Michael J. Keating, MD, William G. Wierda, MD, PhD, Julia Hoellenriegel, Alessandra Ferrajoli, M.D., Stefan Faderl, MD, Susan Lerner, MS, Gracy Zacharian, Xuelin Huang, PhD, Danelle F. James, M.D., Joseph J. Buggy, PhD, Hagop M Kantarjian, Susan M. O'Brien

Blood (2012) 120 (21): 187.

DOI: https://doi.org/10.1182/blood.V120.21.187.187

Published: 2012

Journal Articles

The PI3 Kinase δ Inhibitor, CAL-101 (GS-1101), Inhibits Chronic Lymphocytic Leukemia (CLL) Cell Survival in Endothelial and Marrow Stromal Cell Co-Cultures.

Stefania Fiorcari, Wells S Brown, Bradley W McIntyre, PhD, Susan O'Brien, MD, Mariela Sivina, PhD, Julia Hoellenriegel, William G. Wierda, MD, PhD, Michael J Keating, MD, Roberto Marasca, Brian J. Lannutti, PhD, Zeev Estrov, Jan A. Burger, MD, PhD

Blood (2011) 118 (21): 1769.

DOI: https://doi.org/10.1182/blood.V118.21.1769.1769

Published: 2011

Journal Articles

The Spiegelmer Nox-A12, a Novel SDF-1 (CXCL12) Inhibitor, and Its Effects on Chronic Lymphocytic Leukemia (CLL) Cell Migration,

Julia Hoellenriegel, Dirk Zboralski, PhD, Zeev Estrov, William G. Wierda, MD, PhD, Michael Keating, MD, Anna Kruschinski, PhD, Jan A. Burger, MD, PhD

Blood (2011) 118 (21): 3878.

DOI: https://doi.org/10.1182/blood.V118.21.3878.3878

Published: 2011

Journal Articles

The phosphoinositide 3′-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia

Julia Hoellenriegel, Sarah A. Meadows, Mariela Sivina, William G. Wierda, Hagop Kantarjian, Michael J. Keating, Neill Giese, Susan O'Brien, Albert Yu, Langdon L. Miller, Brian J. Lannutti, Jan A. Burger

Blood (2011) 118 (13): 3603–3612.

DOI: https://doi.org/10.1182/blood-2011-05-352492

Published: 2011

Includes: Supplemental data

Journal Articles

Spleen Tyrosine Kinase (Syk) Inhibitors Block B Cell Receptor Signaling and Survival In Chronic Lymphocytic Leukemia

Julia Hoellenriegel, Greg Coffey, PhD, Uma Sinha, PhD, Anjali Pandey, PhD, William G. Wierda, MD, PhD, Michael J Keating, MD, Jan A. Burger, MD, PhD

Blood (2010) 116 (21): 3604.

DOI: https://doi.org/10.1182/blood.V116.21.3604.3604

Published: 2010

Journal Articles

Phosphoinositide 3’-Kinase (PI3K) Delta Inhibition with CAL-101 Blocks B-Cell Receptor (BCR) Signaling and the Prosurvival Actions of Nurslike Cells (NLC), In Chronic Lymphocytic Leukemia

Julia Hoellenriegel, Sarah A Meadows, William G. Wierda, MD, PhD, Michael J Keating, MD, Brian Lannutti, PhD, Jan A. Burger, MD, PhD

Blood (2010) 116 (21): 48.

DOI: https://doi.org/10.1182/blood.V116.21.48.48

Published: 2010

NARROW

The Landscape of Dynamic Genetic Changes in Ibrutinib-Treated CLL

Identification of B Cell Receptor Antigens in the Chronic Lymphocytic Leukemia Microenvironment

The Spiegelmer NOX-A12, a novel CXCL12 inhibitor, interferes with chronic lymphocytic leukemia cell motility and causes chemosensitization

Longitudinal Gene Expression Profiling Reveals Down-Regulation Of BCR Signaling-Related Genes In Chronic Lymphocytic Leukemia (CLL) Patients Treated With Ibrutinib Plus Rituximab

Clonal Evolution In Patients With Chronic Lymphocytic Leukemia (CLL) Developing Resistance To BTK Inhibition

Ibrutinib In Combination With Rituximab (iR) Is Well Tolerated and Induces a High Rate Of Durable Remissions In Patients With High-Risk Chronic Lymphocytic Leukemia (CLL): New, Updated Results Of a Phase II Trial In 40 Patients

Mode of Action of the SDF-1/CXCL12 Inhibiting Spiegelmer ® Nox-A12 and Its Impact On Chronic Lymphocytic Leukemia (CLL) Cell Motility and Chemosensitization

In Vivo Inhibition of BCR Activation in High-Risk CLL Patients On Therapy with Bruton's Tyrosine Kinase Inhibitor Ibrutinib: Correlative Studies from an Ongoing Phase 2 Clinical Trial

The Btk Inhibitor Ibrutinib (PCI-32765) in Combination with Rituximab Is Well Tolerated and Displays Profound Activity in High-Risk Chronic Lymphocytic Leukemia (CLL) Patients

The PI3 Kinase δ Inhibitor, CAL-101 (GS-1101), Inhibits Chronic Lymphocytic Leukemia (CLL) Cell Survival in Endothelial and Marrow Stromal Cell Co-Cultures.

The Spiegelmer Nox-A12, a Novel SDF-1 (CXCL12) Inhibitor, and Its Effects on Chronic Lymphocytic Leukemia (CLL) Cell Migration,

The phosphoinositide 3′-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia

Spleen Tyrosine Kinase (Syk) Inhibitors Block B Cell Receptor Signaling and Survival In Chronic Lymphocytic Leukemia

Phosphoinositide 3’-Kinase (PI3K) Delta Inhibition with CAL-101 Blocks B-Cell Receptor (BCR) Signaling and the Prosurvival Actions of Nurslike Cells (NLC), In Chronic Lymphocytic Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only